|
1
|
Popovic LS, Matovina-Brko G and Popovic M:
Checkpoint inhibitors in the treatment of urological malignancies.
ESMO open. 2:e0001652017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siddiqui MR, Grant C, Sanford T and
Agarwal PK: Current clinical trials in non-muscle invasive bladder
cancer. Urol Oncol. 35:516–527. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zlatev DV, Altobelli E and Liao JC:
Advances in imaging technologies in the evaluation of high-grade
bladder cancer. Urol Clin North Am. 42147–157. (vii)2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bellmunt J, Orsola A, Leow JJ, Wiegel T,
De Santis M and Horwich A; ESMO Guidelines Working Group, : Bladder
cancer: ESMO Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 25 (Suppl 3):iii40–iii48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Papanicolaou KN, Kikuchi R, Ngoh GA,
Coughlan KA, Dominguez I, Stanley WC and Walsh K: Mitofusins 1 and
2 are essential for postnatal metabolic remodeling in heart.
Circulation research. 111:1012–1026. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chan DC: Mitochondria: Dynamic organelles
in disease, aging, and development. Cell. 125:1241–1252. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo X, Chen KH, Guo Y, Liao H, Tang J and
Xiao RP: Mitofusin 2 triggers vascular smooth muscle cell apoptosis
via mitochondrial death pathway. Circ Res. 101:1113–1122. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bach D, Pich S, Soriano FX, Vega N,
Baumgartner B, Oriola J, Daugaard JR, Lloberas J, Camps M, Zierath
JR, et al: Mitofusin-2 determines mitochondrial network
architecture and mitochondrial metabolism. A novel regulatory
mechanism altered in obesity. J Biol Chem. 278:17190–17197. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zuchner S, Mersiyanova IV, Muglia M,
Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E,
Patitucci A, Senderek J, et al: Mutations in the mitochondrial
GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A.
Nat Genet. 36:449–451. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu K, Chen G, Li X, Wu X, Chang Z, Xu J,
Zhu Y, Yin P, Liang X and Dong L: MFN2 suppresses cancer
progression through inhibition of mTORC2/Akt signaling. Sci Rep.
7:417182017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang GE, Jin HL, Lin XK, Chen C, Liu XS,
Zhang Q and Yu JR: Anti-tumor effects of Mfn2 in gastric cancer.
Int J Mol Sci. 14:13005–13021. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang G and McKenney JK: Urinary Bladder
Pathology: World Health Organization (WHO) Classification and
American Joint Committee on Cancer (AJCC) Staging Update. Arch
Pathol Lab Med. 143:571–577. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cui Y, Ma W, Lei F, Li Q, Su Y, Lin X, Lin
C, Zhang X, Ye L, Wu S, et al: Prostate tumour overexpressed-1
promotes tumourigenicity in human breast cancer via activation of
Wnt/beta-catenin signalling. J Pathol. 239:297–308. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen G, Liu N, Zhou A, Tang C, Ma D and
Tang J: The role of hypertension-related gene in aortic vascular
smooth muscle cells from mice and rats. Chin Med J (Engl).
114:833–836. 2001.PubMed/NCBI
|
|
16
|
Cao YL, Meng S, Chen Y, Feng JX, Gu DD, Yu
B, Li YJ, Yang JY, Liao S, Chan DC and Gao S: MFN1 structures
reveal nucleotide-triggered dimerization critical for mitochondrial
fusion. Nature. 542:372–376. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abdelwahid E, Li H, Wu J, Irioda AC, de
Carvalho KA and Luo X: Endoplasmic reticulum (ER) stress triggers
Hax1-dependent mitochondrial apoptotic events in cardiac cells.
Apoptosis. 21:1227–1239. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Y and Dorn GW II:
PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling
damaged mitochondria. Science. 340:471–475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jin B, Fu G, Pan H, Cheng X, Zhou L, Lv J,
Chen G and Zheng S: Anti-tumour efficacy of mitofusin-2 in urinary
bladder carcinoma. Med Oncol. 28 (Suppl 1):S373–S380. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang W, Xie Q, Zhou X, Yao J, Zhu X, Huang
P, Zhang L, Wei J, Xie H, Zhou L and Zheng S: Mitofusin-2 triggers
mitochondria Ca2+ influx from the endoplasmic reticulum to induce
apoptosis in hepatocellular carcinoma cells. Cancer Lett.
358:47–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lou Y, Li R, Liu J, Zhang Y, Zhang X, Jin
B, Liu Y, Wang Z, Zhong H, Wen S and Han B: Mitofusin-2
over-expresses and leads to dysregulation of cell cycle and cell
invasion in lung adenocarcinoma. Med Oncol. 32:1322015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Feng X, Zhu K, Liu J, Chen J, Tang J,
Liang Y, Jin R, Liang X and Cai X: The evaluative value of Sema3C
and MFN2 co-expression detected by immunohistochemistry for
prognosis in hepatocellular carcinoma patients after hepatectomy.
Onco Targets Ther. 9:3213–3221. 2016.PubMed/NCBI
|
|
23
|
Fang CL, Sun DP, Chen HK, Lin CC, Hung ST,
Uen YH and Lin KY: Overexpression of Mitochondrial GTPase MFN2
represents a negative prognostic marker in human gastric cancer and
its inhibition exerts anti-cancer effects. J Cancer. 8:1153–1161.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou X, Zhang L, Zheng B, Yan Y, Zhang Y,
Xie H, Zhou L, Zheng S and Wang W: MicroRNA-761 is upregulated in
hepatocellular carcinoma and regulates tumorigenesis by targeting
Mitofusin-2. Cancer Sci. 107:424–432. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma LI, Chang Y, Yu L, He W and Liu Y:
Pro-apoptotic and anti-proliferative effects of mitofusin-2 via
PI3K/Akt signaling in breast cancer cells. Oncol Lett.
10:3816–3822. 2015. View Article : Google Scholar : PubMed/NCBI
|
